MIC breakpoints

  • Ceftazidime-Avibactam Susceptibility Breakpoints against <span class="named-content genus-species" id="named-content-1">Enterobacteriaceae</span> and <span class="named-content genus-species" id="named-content-2">Pseudomonas aeruginosa</span>
    Clinical Therapeutics
    Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

    Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8...

    Wright W. Nichols, Gregory G. Stone, Paul Newell, Helen Broadhurst, Angela Wardman, Merran MacPherson, Katrina Yates, Todd Riccobene, Ian A. Critchley, Shampa Das
Back to top